Accelerated approval targets a post–PD-1-refractory population with limited established options, encompassing unresectable advanced cutaneous melanoma after progression on prior PD-1–based therapy.

Diagnosed with stage 1 lung cancer at 40, Gillian Ryan shares the overwhelming guilt she felt about bringing cancer into her family’s life. When Gillian Ryan was diagnosed with stage 1 non-small cell ...

Two breast cancer episodes over 15 years constrained broader life activities, underscoring how prolonged survivorship can narrow time, finances, and psychological reserve beyond direct medical demands ...

In an interview with CURE, Dr. Mark Zhao, a colorectal surgeon at UCSF Health specializing in colorectal cancer and pelvic floor disorders, discussed transanal minimally invasive surgery, the single ...

Advisory committee deliberations focused on causal attribution in a single-arm study and whether clinical benefit can be distinguished from nivolumab effect, despite favorable response durability ...

Follicular lymphoma survivorship carries enduring relapse vigilance; “risk drops” does not equate to baseline risk restoration even years after completing therapy. Small interval decreases in ...

In this installment of the balance exercise series, physical therapist Leslie Waltke walks us through a move called the ...

Luciana Lopes Manfredini, BSN, PhD, of Einstein Hospital Israelita in São Paulo, Brazil, developed a triage scale for ...

Diagnosed with limited-stage small-cell lung cancer, Tammy shares how treatment progress and a mindset shift helped her find hope. When Tammy received her diagnosis in September 2023, the news was as ...

Papillary thyroid carcinoma is often minimized clinically, yet treatment can impose substantial burdens, including radioactive iodine isolation, abrupt menopausal symptoms, and lifelong thyroid ...

Melanie Diaz, DNP, NP-C, OCN, of St. Francis Cancer Institute, blends firm accountability with deep empathy to keep cancer patients engaged and empowered throughout treatment.